We promote the understanding of assessment and access processes for life science products to support the development and adoption of innovative treatments
EU health technology assessment authorities have set disclosure, oversight and accountability expectations for artificial intelligence used to prepare evidence for Joint Clinical Assessments.
Spain has established common referral, funding and follow-up arrangements intended to improve equity of access for patients who need high-complexity pharmaceutical treatment in another autonomous community.
